Výsledky vyhledávání - "ANNABEL BARRETT"

738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes

Autor: MARTIN FUECHTENBUSCH, BRUNO GUERCI, FRANCESCO GIORGINO, LUIS-EMILIO GARCIA-PEREZ, ELKE HEITMANN, JEREMIE LEBREC, ANNABEL BARRETT, ANNE DIB, MARCO ORSINI FEDERICI, KRISTINA BOYE

Publikováno v: Diabetes. 71

Data on patient-reported outcome (PRO) measures in people living with T2D who initiate injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication in routine clinical practice are limited. Here we present final PRO data from the TROPHIE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f5e8e06eb9893cb260968c41a07c9a2
https://doi.org/10.2337/db22-738-p

Zobrazit plný text záznamu

Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS)

Autor: Annabel Barrett, Franz Jakob, Fernando Marin, Gérald Rajzbaum, Astrid Fahrleitner-Pammer, Bente L. Langdahl, J. Bernard Walsh, Willem F. Lems, Östen Ljunggren, Dimitrios Karras

Publikováno v: Calcified Tissue International, 90(5), 373-383. Springer New York
Walsh, J B, Lems, W F, Karras, D, Langdahl, B L, Ljunggren, O, Fahrleitner-Pammer, A, Barrett, A, Rajzbaum, G, Jakob, F & Marin, F 2012, ' Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis : 36-month results from the European Forsteo Observational Study (EFOS) ', Calcified Tissue International, vol. 90, no. 5, pp. 373-83 . https://doi.org/10.1007/s00223-012-9590-9
Walsh, J B, Lems, W F, Karras, D, Langdahl, B L, Ljunggren, O, Fahrleitner-Pammer, A, Barrett, A, Rajzbaum, G, Jakob, F & Marin, F 2012, ' Effectiveness of Teriparatide in Women Over 75 Years of Age with Severe Osteoporosis: 36-Month Results from the European Forsteo Observational Study (EFOS) ', Calcified Tissue International, vol. 90, no. 5, pp. 373-383 . https://doi.org/10.1007/s00223-012-9590-9
Calcified Tissue International

This predefined analysis of the European Forsteo Observational Study (EFOS) aimed to describe clinical fracture incidence, back pain, and health-related quality of life (HRQoL) during 18 months of teriparatide treatment and 18 months post-teriparatid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99f5715d8181876d8134848b1b23820
https://hdl.handle.net/1871/42689

Zobrazit plný text záznamu

Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis : the European Forsteo Observational Study

Autor: Willem F. Lems, Annabel Barrett, Astrid Fahrleitner-Pammer, Franz Jakob, Fernando Marin, Dimitrios Karras, Ivaylo Stoykov, Gérald Rajzbaum, Bente L. Langdahl, Östen Ljunggren, J. Bernard Walsh

Publikováno v: BMC Musculoskeletal Disorders, 14:251. BioMed Central
Ljunggren, Ö, Barrett, A, Stoykov, I, Langdahl, B L, Lems, W F, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Jakob, F, Karras, D & Marin, F 2013, ' Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis : the European Forsteo Observational Study ', B M C Musculoskeletal Disorders, vol. 14, pp. 251 . https://doi.org/10.1186/1471-2474-14-251
BMC Musculoskeletal Disorders
Ljunggren, O, Barrett, A, Stoykov, I, Langdahl, B L, Lems, W F, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Jakob, F, Karras, D & Marin, F 2013, ' Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study ', BMC Musculoskeletal Disorders, vol. 14, 251 . https://doi.org/10.1186/1471-2474-14-251

Background: To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b6fce80a4a48fd67548b578e64f0b55
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-208079

Zobrazit plný text záznamu

Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study

Autor: Franz Jakob, I. Stoykov, Östen Ljunggren, Fernando Marin, Annabel Barrett, J. B. Walsh, Dimitrios Karras, Astrid Fahrleitner-Pammer, Bente L. Langdahl, Gérald Rajzbaum, Willem F. Lems

Publikováno v: Journal of Rheumatology, 39(3), 600-609. Journal of Rheumatology
Karras, D, Stoykov, I, Lems, W F, Langdahl, B L, Ljunggren, O, Barrett, A, Walsh, J B, Fahrleitner-Pammer, A, Rajzbaum, G, Jakob, F & Marin, F 2012, ' Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study ', Journal of Rheumatology, vol. 39, no. 3, pp. 600-609 . https://doi.org/10.3899/jrheum.110947

Objective.To describe clinical fracture rates, back pain, and health-related quality of life (HRQOL) in postmenopausal women with osteoporosis who are receiving glucocorticoids (GC), during a 36-month study of teriparatide treatment for up to 18 mont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27d23acf678e41b83336a81951ab9af
https://pubmed.ncbi.nlm.nih.gov/22383352

Zobrazit plný text záznamu

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

Autor: Bente L. Langdahl, Astrid Fahrleitner-Pammer, Gérald Rajzbaum, Östen Ljunggren, Heide Oertel, Clare Barker, Dimitrios Karras, Franz Jakob, Willem F. Lems, Annabel Barrett, James Bernard Walsh, Fernando Marin

Publikováno v: European Journal of Endocrinology
European Journal of Endocrinology, 166(1), 87-97. BioScientifica Ltd.
Jakob, F, Oertel, H, Langdahl, B, Barrett, A, Karras, D, Walsh, J B, Fahrleitner-Pammer, A, Razjbaum, G, Barker, C, Lems, W F & Marin, F 2012, ' Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36 month results from the European Forsteo Observational Study ', European Journal of Endocrinology, vol. 166, no. 1, pp. 87-97 . https://doi.org/10.1530/EJE-11-0740

ObjectivesTo describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad71fc9ee43eefb8a8a3d4a65460085
https://pubmed.ncbi.nlm.nih.gov/22048967

Zobrazit plný text záznamu

Fracture rate and back pain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study

Autor: Dimitrios Karras, Bente L. Langdahl, Willem F. Lems, Annabel Barrett, Östen Ljunggren, Astrid Fahrleitner-Pammer, J. B. Walsh, Franz Jakob, Clare Barker, Gérald Rajzbaum, Fernando Marin

Publikováno v: Fahrleitner-Pammer, A, Langdahl, B, Marin, F, Jakob, F, Karras, D, Barrett, A, Ljunggren, O, Walsh, J B, Rajzbaum, G, Barker, C & Lems, W F 2011, ' Fracture rate and back pain during and after discontinuation of teriparatide: 36 month data from the European Forsteo Observational Study ', Osteoporosis International, vol. 22, no. 10, pp. 2709-2719 . https://doi.org/10.1007/s00198-010-1498-5
Osteoporosis International
Osteoporosis International, 22(10), 2709-2719. Springer London
Fahrleitner-Pammer, A, Langdahl, B L, Marin, F, Jakob, F, Karras, D, Barrett, A, Ljunggren, Ö, Walsh, J, Rajzbaum, G, Barker, C & Lems, W 2010, ' Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS) ', Osteoporosis International . https://doi.org/10.1007/s00198-010-1498-5

Summary In this observational study in postmenopausal women with severe osteoporosis, the incidence of fractures was decreased during 18 months of teriparatide treatment with no evidence of further change in the subsequent 18-month post-teriparatide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7655f9a2f0dbdec44d6cac8126d0b802
https://research.vumc.nl/ws/files/792700/275368.pdf

Zobrazit plný text záznamu

Fracture incidence, quality of life and back pain in women with osteoporosis pretreated with bisphosphonates: 36 month results from the European forsteo observational study (EFOS)

Autor: B. Walsh, Franz Jakob, Clare Barker, Gérald Rajzbaum, Fernando Marin, Willem F. Lems, Annabel Barrett, Astrid Fahrleitner-Pammer, Bente L. Langdahl, Östen Ljunggren, Dimitrios Karras

Publikováno v: Bone. 47:S193

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c0c0de28a6c4ce2f56ae0801e9ab7531
https://doi.org/10.1016/j.bone.2010.04.457

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání